Bax:Bcl2 Cancer Research Results
Bax:Bcl2, Bax:Bcl2 ratio: Click to Expand ⟱
| Source: |
| Type: |
Bax and Bcl-2 are the major members of Bcl-2 family that play a key role in tumor progression or inhibition of intrinsic apoptotic pathway triggered by mitochondrial dysfunction.
Bax/Bcl-2 ratio is typically significantly lower in tumors.
|
Scientific Papers found: Click to Expand⟱
| - |
in-vivo, |
AD, |
NA |
|
|
|
- |
in-vivo, |
Park, |
NA |
|
|
|
*neuroP↑, Given that fisetin exerts neuroprotection
*Dose↝, Fisetin (15 mg/Kg. b.wt. orally) was administered for 4 weeks before AlCl3-induction and administered simultaneously for 8 weeks during AlCl3-induction.
*Aβ↓, fisetin significantly (P<0.05) reduced Aβ aggregation, ASK-1, p-JNK, p53, cytochrome c, caspase-9 and 3 protein expressions and modulated Bax/Bcl-2 ratio.
*ASK1↓,
*p‑JNK↓,
*P53↓,
*Cyt‑c↓,
*Casp9↓,
*Bax:Bcl2↝,
Showing Research Papers: 1 to 1 of 1
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1
Pathway results for Effect on Cancer / Diseased Cells:
Total Targets: 0
Pathway results for Effect on Normal Cells:
Cell Death(tgid=5) ⓘ
ASK1↓, 1, Bax:Bcl2↝, 1, Casp9↓, 1, Cyt‑c↓, 1, p‑JNK↓, 1,
DNA Damage & Repair(tgid=10) ⓘ
P53↓, 1,
Protein Aggregation(tgid=19) ⓘ
Aβ↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
Dose↝, 1,
Functional Outcomes(tgid=23) ⓘ
neuroP↑, 1,
Total Targets: 9
Scientific Paper Hit Count for: Bax:Bcl2, Bax:Bcl2 ratio
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:352 State#:% Dir#:4
wNotes=on sortOrder:rid,rpid
Home Page